



Breast Oncology Research Presentations

2022 San Antonio Breast Cancer Symposium®

All times are CENTRAL Time

Day 1: Tuesday, Dec 6th

Time	Name	Title	Session	Location
8:00–9:00 am	N. Tayob	Statistical considerations for precision medicine	Clinical Research Workshop	Stars at Night Ballroom 1&2
10:00–12:00 pm	Alan D. d'Andrea, MD	Pol-theta inhibitors in HRD tumors	Educational Session #1C New Agents Targeting HRD in Breast Cancer	
2:00–5:00 pm	A. Partridge	Moderator	GENERAL SESSION #1	Hall 3
5:00–6:15 pm	A. Waks	Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial	Poster presentation P1-04-05	Poster session 1" Hemisfair Ballroom
5:00 pm	Hamilton EP (Giordano)	XMT-1660: A Phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers	Ongoing Trials Poster Session 1	
5:00 pm	Braunstein LZ (Bellon J)	Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer	Ongoing Trials Poster Session 1	



Day 2: Wednesday, Dec 7th

Time	Name	Title	Session	Location
7:00–8:15 am	R. Freedman	Geriatric Breast Cancer	Spotlight Poster Discussion Session: Special Populations: Male Breast Cancer/ Geriatrics	Stars at Night Ballroom 1&2
7:00–8:15 am	J.P. Jose Leone	Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer.	Spotlight Poster Discussion Session: Special Populations: Male Breast Cancer/ Geriatrics	
7:00–8:15 am	S. Morganti	Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib Poster ID: P2-01-02	Spotlight Poster Discussion Session	
7:00–8:15 am	O. Metzger	Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma	Poster Presentation P2-03-13	Poster Session 2 Stars at Night Ballrooms 1&2
7:00–8:15 am	L. Rosenberger (Sammons)	Genomic Evaluation of Malignant Phyllodes Tumors Reveals Multiple Targetable Opportunities	Poster Presentation	
9:45–11:00 am	P. Tarantino	HER2-05 Comprehensive genomic characterization of HER2-low breast cancer	Poster HER2 Low: A Separate Entity Special Session	Hall 3
9:45–11:00 am	A. Garrido-Castro	HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer	Poster HER2 Low: A Separate Entity Special Session	Hall 3
9:45–11:00 am	R. Bansal (Sammons)	Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer	Poster	

Continued over



Day 2: Wednesday, Dec 7th (Continued)

Time	Name	Title	Session	Location
11:00–12:00 pm	R. Jeselsohn	Houston, THER2 signaling the ER cistrome	Mini-Symposium #1 C. Kent Osborne HER2 and ER Crosstalk: Signaling Mechanisms and Clinical Implications Symposium	Hall 3
5:00–6:15 pm	S. Tolaney	Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in HR+/HER2-metastatic breast cancer (MBC) Poster ID: P3-07-08	Poster Session 3	
5:00–6:15 pm	E. Mayer	evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer. Poster ID: OT2-01-07	Ongoing Trials Poster Session 2	
5:00 pm	N. Lin	Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer: DESTINY-Breast12	Ongoing Trials Poster Session 2	
5:00–6:15 pm	R. Freedman	Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)	Spotlight Poster Discussion Session	
5:00–6:15 pm	J.P. Jose Leone	Survival of patients with brain metastases at initial breast cancer diagnosis over the last decade	Spotlight Poster Discussion Session	

Continued over



Day 2: Wednesday, Dec 7th (Continued)

Time	Name	Title	Session	Location
5:00–6:00 pm	I.M. Vaz-Duarte	Symptom Management	Spotlight Poster Discussion session #8:	Stars at Night Ballroom 1&2
5:00–6:00 pm	Carmeli AB (C. Block, N. Wagle)	Real-world time-to-treatment discontinuation in hormone-receptor-positive metastatic breast cancer patients following CDK4/6 inhibitor treatment, based on observational data collected through patient-partnered research	Poster Session 3	
5:00–6:00 pm	O'Shaughnessy J (S. Tolaney)	Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis	Poster Session 3	
5:00–6:00 pm	Mukhopadhyay S (CA Bunnell)	Prediction of disease recurrence in low risk Oncotype Dx breast cancers from digital H&E-stained whole slide images of pre-treatment resections alone	Poster Session	
5:00–6:15 pm	Van den Bruele (Sammons)	Low 21-Gene Recurrence Score Is Not Associated with a High Axillary Nodal Burden in Post-Menopausal Women Presenting with a Clinically Negative Axilla	Poster session	
5:00–6:15 pm	S. Kabraji	Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis	Spotlight Poster Discussion 7	



Day 3: Thursday, Dec 8th

Time	Name	Title	Session	Location
7:00–8:15 am	J. Ligibel	Spotlight poster discussion on “Obesity and Breast Cancer”	Discussant in a Spotlight Poster Discussion	Ballroom 1&2
7:00–8:15 am	Faina Nakhlis	Long-term Outcomes After 1 or 2-3 Lines of Neoadjuvant Therapy in Stage III Inflammatory Breast Cancer	Poster Presentation	
7:00–8:15 am	A. Garrido-Castro	Poster ID: P4-07-14	Poster Presentation.	
7:00–8:15 am	H. Parsons	Dynamics of HER2-low expression in triple-negative breast cancer	Spotlight Poster Discussion	
7:00–8:15 am	Miller K (S. Tolaney)	Poster ID: P4-08-08	Poster	
7:00–8:15 am	Patnaik A (G. Shapiro)	Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 Poster ID: PD11-06	Poster	
7:00–8:15 am	Romanos-Nanclares A (W. Chen)	Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer(ABC)	Poster	
7:00–8:15 am	Marmé F (S. Tolaney)	A phase 1 study of the oral CDK7 inhibitor XL102 as a single agent and in combination therapy in patients With advanced solid tumors (QUARTZ-101): Initial results from the dose-escalation stage	Poster	
7:00–8:15 am	Schade A (A. Garrido-Castro)	Proinflammatory dietary patterns and risk of total and subtypes of breast cancer among US women	Poster	
7:00–8:15 am	Domingos TA (Mittendorf)	Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2-metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial	Poster	
7:00–8:15 am	S. Sammons	AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution	Poster	

Continued over



Day 3: Thursday, Dec 8th (Continued)

Time	Name	Title	Session	Location
7:00–8:15 am	H. Moore (Sammons)	Evaluating the safety of tucatinib in combination with trastuzumab and capecitabine for human epidermal growth factor 2 (HER2)-positive metastatic breast cancer in a real-world setting	Poster	
9:00–9:15 am	Hurvitz SA (R. Jeselsohn)	GS3-03 ARV-471, a PROTAC [®] estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study	General Session #3	Hall 3
9:45 am	R. Jeselsohn	Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer Presentation ID: GS3-06	Oral Slide Presentation	
9:45–10:00 am	E. Mayer	GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer	General Session 3 Oral Slide Presentation	Hall 3
10:00–10:15 am	Guarducci C (Jeselsohn R)	GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer	General Session 3	
2:00–3:00 pm	G. Shapiro	RIP MTD	Translational Controversies	Stars at Night Ballroom 1&2
2:00–3:00 pm	Jeselsohn R	Demystifying CDKs in Breast Cancer: Beyond CDK4/6 Moderator	Forum #4	Stars at Night Ballroom 3&4
3:00–5:00 pm	Lynce F.	Challenging Types of Breast Cancer: Inflammatory	Educational Session Block #3B:	Stars at Night Ballroom 1&2
3:00–5:00 pm	Parsons H	What ctDNA Can Tell Us: Which is the best technique	Educational Session Block #3C:	

Continued over



Day 3: Thursday, Dec 8th (Continued)

Time	Name	Title	Session	Location
5:00–6:15 pm	Hope Rugo	Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer Poster ID: PD13-06	Spotlight Poster Discussion Session	
5:00–6:15 pm	P. Tarantino	Comprehensive genomic characterization of HER2-low breast cancer Poster ID: P5-13-02		
5:00–6:15 pm	S. Tolaney	Biomarker analyses from the Phase 2 AMEERA-3 study of amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in patients with ER+/HER2– advanced breast cancer (aBC) Poster ID: PD13-03	Spotlight Poster Discussion Session	
5pm–6:15 pm	Michele Bottosso (J. Garber)	HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome. Poster ID P5-02-18	Poster	
5:00–6:15 pm	R. Jeselsohn	Therapeutic Approaches for HR+/Her2- Breast Cancer	Spotlight Poster Discussion	Stars at Night Ballroom 1&2
5:00–6:15 pm	Renata Sandoval	The effect of timing of TP53 genetic testing on treatment and outcomes among women with Li-Fraumeni syndrome and breast cancer Poster ID: PD14-09	Spotlight Poster Discussion Session	
5:00–6:15 pm	S. Morganti	Clonal hematopoiesis of indeterminate potential after (neo) adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study Poster ID: P5-14-03	Spotlight Poster Discussion Session	
5:00–6:15 pm	K. Sorouri (A. Partridge)	Conception and Pregnancy Among Young Breast Cancer Survivors Poster ID: P5-08-05	Poster Presentation	

Continued over



Day 3: Thursday, Dec 8th (Continued)

Time	Name	Title	Session	Location
5:00–6:00 pm	Antonio (Sarah Mutka)	A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1) Poster ID: OT3-26-02	Poster	
5:00–6:00 pm	Egleston B (J. Garber)	Changes in preferences for ovarian cancer prevention strategies during the COVID-19 pandemic: Results of a discrete choice experiment	Poster	
5:00–6:00 pm	Gupta HV (Lin +)	Tumor genomic landscape in older women with metastatic breast cancer (MBC)	Poster	
5:00–6:00 pm	Nguyen TH (Mittendorf +)	Quantitative analysis of fiber-level collagen features in H&E whole-slide images predicts neoadjuvant therapy response in patients with HER2+ breast cancer	Poster	
5:00–6:00 pm	Bottosso M (Garber +)	HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome	Poster	
5:00–6:00 pm	Cespedes Feliciano EM (Dillon +)	Adiposity and immune-related gene expression in the breast tumor microenvironment	Poster	
5:00–6:00 pm	Egleston B (Garber J)	Changes in preferences for ovarian cancer prevention strategies during the COVID-19 pandemic: Results of a discrete choice experiment	Poster	
5:00–6:00 pm	Wehbe A (King +)	Breast imaging recommendations for females < 40 years of age with ≥20% lifetime breast cancer risk: Practice patterns at a specialized clinic	Poster	
5:00–6:00 pm	Sella T	Breastfeeding in survivors of early breast cancer	Poster	

Continued over



Day 3: Thursday, Dec 8th (Continued)

Time	Name	Title	Session	Location
5:00–6:00 pm	Batalini F (Garber)	Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers	Poster	
5:00–6:00 pm	Desmedt C (Metzger O)	Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial	Poster	
5:00–6:00 pm	Hurvitz SA	A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)	Ongoing Trials Poster Session 3	
5:00–6:00 pm	Connolly JJ (King T +)	TBCRC-053: P-RAD: A randomized study of preoperative chemotherapy, Pembrolizumab and no, low or high dose rADiation in node-positive, HER2-negative breast cancer	Ongoing Trials Poster Session 3	
5:00–6:15 pm	M. Goetz (Sammons)	Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study		

*Author list: Alexandra, Fisher Katlin, Eshita Sharma, Marybeth Hans, Mary Graichen, Brittany L. Bychkovsky MD, Rochelle Scheib, Judy E. Garber, Lydia E. Pace, Tari King, Alison Laws



Day 4: Friday, Dec 9th

Time	Name	Title	Session	Location
7:00am–6:15 pm		ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1 Poster ID: PD18-09	Spotlight Poster Discussion Session	
7:00 –8:15 am	S.Tolaney?	Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: final 10-year analysis Poster ID: PD18-02	Spotlight Poster Discussion Session	
7:00–8:15 am	P.Tarantino	Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) Poster ID: PD18-01	Spotlight Poster Discussion Session	
7:00–8:15 am	Factor R (Partridge)	Centralized adequacy assessment of ductal carcinoma in situ samples for the COMET study (AFT-25)	Poster	
7:00–8:15 am	Daly M (Garber)	Identifying preferences that may motivate choice of ovarian cancer risk prevention strategies using a discrete choice experiment	Poster	
7:00–8:15 am	Rosenberg SM (Parsons)	Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC)	Poster	
7:00–8:15 am	Loch MM (Lin N)	Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status	Poster	
7:00–8:15 am	Hutcheson LB (Metzger O)	Lobular Breast Cancer Alliance Inc. Survey of Individuals with Metastatic Invasive Lobular Carcinoma	Poster	

Continued over



Day 4: Friday, Dec 9th (Continued)

Time	Name	Title	Session	Location
7:00–8:15 am	G. Kimmick	Best Quality of Care from a Distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, patient participation and satisfaction with the program.		
7:00–8:15 am	S. Sammons	Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2- metastatic breast cancer (mBC)		
7:00–8:15 am	S. Sammons	Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2- metastatic breast cancer (mBC)		
7:00–8:15 am	J. Meisel (Sammons)	Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2- metastatic breast cancer (mBC)		
9:00–11:30 am	A. Partridge	Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive breast cancer: Initial Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13)	Oral slide presentation	
3:00–5:00 pm	A. Partridge	Special treatment issues in this young patient population	EDUCATIONAL SESSION BLOCK #4A	Stars at Night Ballroom 1&2
5:00–5:15 pm	S. Tolaney	View from the Trenches: What will You do on Monday Morning? – Moderator	EDUCATIONAL SESSION BLOCK #4C	Stars at Night Ballroom 1&2